Dr.GastroMayo said:It helps to say which part of this you are uncertain about.
Correct as far as it goes. The part it does not cover is what to do when the honest answer is "not enough data", which is more often than anyone likes.
Ask again with the specifics and you will get a better answer than this one.
Dr.LipidDallas said:NASH/MAFLD therapeutic landscape and liver and MASH: GLP-1 agonists are emerging as potential first-line NASH therapy.
This answered a question I did not know how to ask. I will report back once I have actually tried it.
Dr.GastroMayo said:It helps to say which part of this you are uncertain about.
I read this differently from Dr.GastroMayo, on substance rather than tone. Pushing back on the consensus forming here. Consistency is not the same as correctness, and a board that agrees with itself quickly is usually agreeing with the first person who sounded certain.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsThe figures, for anyone assembling their own picture. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.
Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Tagging this one for the weekly digest.